Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Tenaya Therapeutics $75 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
Natera $400 million follow-on offering
The shares are listed on Nasdaq
Zoetis $1.35 billion senior notes offering
The investment-grade notes are due 2025 and 2032
Metalmark Capital up to $50 million investment in Morgenesis
We advised Metalmark on the transaction
Roivant Sciences $150 million equity offering
We advised the company on its debut SEC-registered primary and secondary offering
Akoya Biosciences $50 million at-the-market program
The common stock is listed on the Nasdaq Global Select Market
Molded Devices acquisition of GlobalMed and Schauenburg-Truplast
We advised Molded Devices on the acquisition and the related financing arrangements
Elevance Health $1.8 billion senior notes offering
The investment-grade notes are due 2025, 2032 and 2052
Walgreens $2.25 billion Summit Health-CityMD acquisition financing
We are advising the lender in connection with the facilities
NextGen Healthcare $275 million convertible senior notes offering
The 3.75% convertible notes are due 2027